© LB Pharmaceuticals., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Dr. Susan G. Kozauer has served as Chief Medical Officer of LB Pharmaceuticals since September 2026. She has more than 20 years of experience spanning early-stage clinical studies through regulatory approval across various neuropsychiatric indications. Dr. Kozauer most recently served as Senior Vice President, Head of Clinical Development at Centessa Pharmaceuticals, where she led the development of orexin agonists in rare hypersomnias and other neuropsychiatric indications. Prior to that, she was Vice President, Clinical Development at Intra-Cellular Therapies, Inc., where her work with CAPLYTA (lumateperone) in schizophrenia, bipolar disorder, major depressive disorder, and pediatric indications resulted in multiple FDA approvals. Earlier in her career, she held clinical development roles at Premier Research and IQVIA and was also a practicing psychiatrist with special interest in treatment resistant depression. Dr. Kozauer received a Bachelor of Arts degree from Cornell University, and a Doctor of Medicine from George Washington University, and completed her residency in psychiatry at Georgetown University Hospital.